RANI Rani Therapeutics Holdings Inc - Ordinary Shares Class A

$RANI Does Rani have short-term expansion plans? Yes, Rani Therapeutics has active and concrete expansion plans for the short and medium term. ​Production Automation: Following its inclusion in the ETP, Rani is specifically focusing on automating its vertically integrated manufacturing process to scale capsule production from clinical trial volumes to commercial-scale manufacturing. ​Capacity and Facility Expansion: Rani is expanding its manufacturing capacity to produce its own drugs and serve as a CDMO/manufacturing partner for major pharmaceutical companies looking to formulate their biologic drugs into the RaniPill. ​Pipeline Expansion (including Obesity): Rani is rapidly expanding its clinical programs, including the development of the RaniPill for obesity treatments (RT-114 GLP-1/GLP-2 dual agonist) and large molecules like antibodies.

$RANI Wat happens is the stock price fails to rise above one dollar? Rani Therapeutics is facing a tight timeline to regain Nasdaq compliance and avoid a potential delisting. ​If the stock price fails to organically rise above $1.00 through positive clinical news or investor confidence in time, the company has concrete options available: ​Requesting an extension: If the initial 180-day grace period expires without compliance, Rani can apply for a second 180-day extension, provided theymeet all other Nasdaq listing requirements and state their intention to cure the deficiency. ​Executing a reverse stock split: This serves as the fastest and most common emergency option. By consolidating shares (for example, combining 10 existing shares into 1 new share), the stock price immediately increases tenfold, placing Rani comfortably back above the $1.00 threshold. ​Let us hope management will reserve a reverse stock split as a last resort.... LET US RISE AND SHINE !!!!

$RANI "Bright the future of Rani is, for trust in management and strong technology, reward the patient investor will!"

$RANI I’ve been flipping this penny stock for more than a year and believe me when I say, it always make me money. Just buy the dip 💚💚💚

$RANI shorts desperate to cover at low levels but no one is selling. Not even 100k volume. Still 7.12 million shares to cover…easily $2- $3.

$RANI oral pill technology has great potential 10- 20% of the world population suffers from a fear of needles ( trypanophobia) America’s youth is the largest needle phobic group

$RANI Great risk to reward with this company. Worse case scenario = delisting and 40 cents a share. We trigger a milestone payment from Chugai and we have the potential to run to $10 a share n the blink of an eye.

$RANI In any case, a reverse stock split requires a shareholder vote—and I haven't found anything on that yet; the vote must take place at least 20 days before the deadline, and the reverse split itself 10 days before the deadline... barring any requests for extensions, etc.

$RANI needs to pull a rabbit out of a hat pronto. Is the son of the Elon Musk of biotech a success or flop? We'll soon find out.

$RANI alongside the upcoming compliance deadline, Q3 window dressing may also have contributed to the slight decline seen recently. Curious to see how it evolves in the coming critical weeks.

$RANI what's your prediction by nov 9th, maintianing 10 straight days of global compliance, downgrading to captital or RS?

$RANI all bio stocks should be given second time extension. Market concentrated towards 5% of companies.

$RANI I wish the management should not let it go on $1 compliance. If they do RS, it will be DISASTER for stock.

$RANI tell me why I should maintain faith with Supply chain risks, delisting risk, competition risk, complexity risks.